Another relevant molecular mechanism explaining its potent therapeutic activity in AML involves the suppression of the SP1/TET1/5hmC/FLT3-HOXA9-MEIS1/MYC signaling pathway (C. Li et al., 2020a). This evidence concerns the gene SP1 and acute myeloid leukemia.